Pyxis Oncology Inc. (PYXS) has emerged as a clinical-stage biopharmaceutical company to watch, with a clear focus on developing innovative therapeutics for difficult-to-treat cancers.
Its lead candidate, micvotabart pelidotin (MICVO), represents a first-in-concept antibody drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix that is largely absent in normal adult tissues. By leveraging this unique target, Pyxis aims to deliver a therapy capable of reshaping treatment outcomes for patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.